Status:
COMPLETED
Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis
Lead Sponsor:
Alcon Research
Conditions:
Vasomotor Rhinitis
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).
Eligibility Criteria
Inclusion
- Diagnosis of VMR with at least 2 years of chronic non-allergic rhinitis
- Negative skin tests to a panel of allergens and positive histamine test within last 2 years
- History of symptoms related to defined VMR triggers
Exclusion
- Nasal disorder, surgery, or concurrent disease that could interfere with evaluation of study medications
- Bacterial or viral infection within 14 days of first visit. Diagnosis of acute sinusitis within 30 days of first visit
- Chronic use of drugs that can cause rhinitis
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT00979615
Start Date
September 1 2009
Last Update
May 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas, United States, 76134